Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME
Aims The EMPA-REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate th...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 December 2020
|
| In: |
ESC heart failure
Year: 2020, Volume: 7, Issue: 6, Pages: 3401-3407 |
| ISSN: | 2055-5822 |
| DOI: | 10.1002/ehf2.12891 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ehf2.12891 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12891 
|
| Author Notes: | Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann and JoAnn Lindenfeld |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1938572467 | ||
| 003 | DE-627 | ||
| 005 | 20251016160440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251016s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ehf2.12891 |2 doi | |
| 035 | |a (DE-627)1938572467 | ||
| 035 | |a (DE-599)KXP1938572467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pellicori, Pierpaolo |e VerfasserIn |0 (DE-588)137912753X |0 (DE-627)1938572343 |4 aut | |
| 245 | 1 | 0 | |a Early benefits of empagliflozin in patients with or without heart failure |b findings from EMPA-REG OUTCOME |c Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann and JoAnn Lindenfeld |
| 264 | 1 | |c 22 December 2020 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.10.2025 | ||
| 520 | |a Aims The EMPA-REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate the early benefit-risk profile of empagliflozin in patients enrolled in the EMPA-REG OUTCOME trial according to HF status at baseline. Methods and results The effects of treatments on glycated haemoglobin, systolic blood pressure and body weight, and on the HF endpoints of hospitalization for HF (HHF), HHF or CV death, and HHF or all-cause mortality were evaluated at 12 weeks, 6 months, and 1 year after randomization. Occurrence of adverse events (AEs) during these time points was also evaluated. Compared with placebo, empagliflozin lowered glycated haemoglobin, systolic blood pressure, and body weight and rates of all the HF endpoints, as early as at 12 weeks, regardless of HF status at baseline. Favourable clinical and metabolic effects were maintained over time. AEs were generally higher in those with HF than without HF; however, compared with placebo, empagliflozin did not increase risk of developing AEs over the first year of treatment. Conclusions In the EMPA-REG OUTCOME trial, the use of empagliflozin led to early and beneficial effects on clinical, metabolic, and HF outcomes in patients with type 2 diabetes with or without HF at baseline, which were already apparent within 12 weeks from initiation of treatment. Over the first year of treatment, no safety concern was detected with the use of empagliflozin. | ||
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a EMPA-REG OUTCOME | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Trial | |
| 700 | 1 | |a Ofstad, Anne Pernille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fitchett, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zeller, Cordula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wanner, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a George, Jyothis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zinman, Bernard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Lindenfeld, JoAnn |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a European Society of Cardiology |t ESC heart failure |d Chichester : Wiley, 2014 |g 7(2020), 6 vom: 22. Dez., Seite 3401-3407 |h Online-Ressource |w (DE-627)820686506 |w (DE-600)2814355-3 |w (DE-576)427947944 |x 2055-5822 |7 nnas |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:6 |g day:22 |g month:12 |g pages:3401-3407 |g extent:7 |a Early benefits of empagliflozin in patients with or without heart failure findings from EMPA-REG OUTCOME |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ehf2.12891 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12891 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251016 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 8 | ||
| 999 | |a KXP-PPN1938572467 |e 4788699524 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1938572467","id":{"eki":["1938572467"],"doi":["10.1002/ehf2.12891"]},"language":["eng"],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 16.10.2025"],"person":[{"display":"Pellicori, Pierpaolo","family":"Pellicori","roleDisplay":"VerfasserIn","given":"Pierpaolo","role":"aut"},{"role":"aut","given":"Anne Pernille","display":"Ofstad, Anne Pernille","family":"Ofstad","roleDisplay":"VerfasserIn"},{"given":"David","role":"aut","roleDisplay":"VerfasserIn","family":"Fitchett","display":"Fitchett, David"},{"given":"Cordula","role":"aut","display":"Zeller, Cordula","family":"Zeller","roleDisplay":"VerfasserIn"},{"given":"Christoph","role":"aut","display":"Wanner, Christoph","family":"Wanner","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Jyothis","roleDisplay":"VerfasserIn","display":"George, Jyothis","family":"George"},{"family":"Zinman","display":"Zinman, Bernard","roleDisplay":"VerfasserIn","given":"Bernard","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Brückmann, Martina","family":"Brückmann","given":"Martina","role":"aut"},{"given":"JoAnn","role":"aut","family":"Lindenfeld","display":"Lindenfeld, JoAnn","roleDisplay":"VerfasserIn"}],"title":[{"title":"Early benefits of empagliflozin in patients with or without heart failure","subtitle":"findings from EMPA-REG OUTCOME","title_sort":"Early benefits of empagliflozin in patients with or without heart failure"}],"origin":[{"dateIssuedDisp":"22 December 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann and JoAnn Lindenfeld"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"ESC heart failure","title_sort":"ESC heart failure"}],"note":["Gesehen am 29.05.2020"],"recId":"820686506","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2814355-3"],"issn":["2055-5822"],"eki":["820686506"]},"language":["eng"],"corporate":[{"display":"European Society of Cardiology","roleDisplay":"VerfasserIn","role":"aut"}],"part":{"year":"2020","text":"7(2020), 6 vom: 22. Dez., Seite 3401-3407","issue":"6","extent":"7","volume":"7","pages":"3401-3407"},"pubHistory":["1.2014 -"],"disp":"European Society of CardiologyESC heart failure","origin":[{"publisherPlace":"Chichester","dateIssuedKey":"2014","publisher":"Wiley","dateIssuedDisp":"2014-"}]}]} | ||
| SRT | |a PELLICORIPEARLYBENEF2220 | ||